Exelixis Inc. and German drugmaker Boehringer Ingelheim GmbH entered a deal potentially worth $354 million to discover, develop and commercialize autoimmune disease therapies. (BioWorld Today)
Shares in Vanda Pharmaceuticals Inc. rocketed into the stratosphere Thursday on news of the FDA's surprising approval of the company's antipsychotic Fanapt. (BioWorld Today)
San Diego-based Amylin has filed for regulatory approval of once weekly exenatide for diabetes, causing a slight jump in its shares and the shares of its partners, Alkermes and Eli Lilly and Co. (BioWorld Today)
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to develop a pen device for delivering exenatide to diabetics, an arrangement in which they will share the initial capital investment of about $216 million, with Lilly making 60 percent of that investment. (BioWorld Today)
Ardea Biosciences Inc. licensed its MEK inhibitors to Bayer Healthcare AG to develop potential treatments for cancer, in a deal worth up to $407 million. (BioWorld Today)
The deteriorating economy, unfavorable currency exchange rate, wholesalers cutting back inventory and U.S. patients foregoing care to save money all contributed to a 4 percent slide in first-quarter earnings at Amgen Inc., company officials said in an earnings call Thursday. (BioWorld Today)
